Diabetes, Heart and Cardiovascular Diseases News Chronicle. Diabetes, Cardiovascular and Heart Diseases. Article 151
Published on March 7, 2017 at 05:30 AM GMT


 



A Breakthrough In Heart Failure Repair With Stem Cells

A study done by researchers from the UK shows repairing of damaged heart tissue with stem cells to prevent heart failure. Initial trial results of the current trial show reversing of scarring by 79 percent and an average 40 percent reduction in heart damage with engineered stem cells known as Heartcel. A high-level meeting paved a way for the researchers to conduct initial trials at two London hospitals with more than 100 patients during autumn. The researchers finalized global trials involving 500 people after discussing with the United States and European regulators.

This technique could end the heart transplant procedures and can lead to heart failure treatment procedure in coming years. Professor Steve Westaby, a cardiac surgeon from John Radcliffe Hospital, Oxford was carrying out the study along with Professor Kim Fox, head of the National Heart and Lung Institute, Imperial College London. The study findings were presented in the European Society of Cell and Gene Therapy, Florence.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below):

Also related to this story
1. Stimulating Bone Stem Cells May Improve Bone Repair
2. Diabetes Link To Loss Of Muscle Stem Cells
3. Trials With Stem Cells
4. Wearable Technology For Elder Care
5. About Meizus H1 Wearable Device

 



Risk With Mouth Bacteria To Cardiovascular Disease

Infective endocarditis is a heart disease caused due to bacteria. The researchers from the University of Bristol, England have identified the molecular process that moves mouth bacteria through the bloodstream to cause infective endocarditis. Previous studies show the formation of blood clots in heart valves due to the bacteria. Mortality rate with blood clots in heart valves is 30 percent. If left untreated, sometimes the result is fatal.

The researchers identified the structure and dynamics of the CshA protein that acts as a "molecular lasso" to enable streptococcus gordonii mouth bacteria to bind to the surface of the human cells. Binding streptococcus gordonii mouth bacteria to human cells is the first step in causing disease. Researchers named this mechanism as "catch-clamp" mechanism. The researchers say development of anti-adhesive agents targeting disease-causing streptococcus gordonii mouth bacteria to prevent them from binding to human cells to treat the disease. Lead author of the study is Dr. Catherine Back and co-author of the study is Dr. Angela Nobbs from School of Oral and Dental Sciences, Bristol University and the study findings were published in the Journal of Biological Chemistry.

 



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below):

Also related to this story
1. Risks With Xerostomia Or Dry Mouth Or Altered Salivary Flow
2. Inflammation, Gut Bacteria Tied to Type 1 Diabetes
3. Mangoes Helps In The Growth Of Gut Bacteria Or Microbiota And Prevents Obesity
4. Risk Of Cardiovascular Diseases With E-cigarettes And Vapers
5. Drug To Treat Infection Behind Cardiovascular Disease

Infective endocarditis : The inner tissue of the heart valves is called endocardium. Inflammation of the endocardium is known as infective endocarditis. Inflammation will be caused due to infectious agents and fungi. This may result in the growth of bacteria on the valves of the heart. Symptoms of inflammation include weakness, discomfort, shortness of breath and fever

 



Slowdown In Diabetic Retinopathy With A Drug Combination

A study done by researchers from the University of Florida, the United States and Erasmus Medical Center, Netherlands shows a successful delay in the development of diabetic retinopathy in rat models with a combination of two drugs. The combination therapy is known as angiotensin receptor neprilysin inhibitor (ARNI). This therapy includes a blood pressure drug (irbesartan) and diarrhoea (or diarrhea) drug (thiorphan). This study was done on rat models for 12 weeks.

The innovative combination therapy can slowdown the development of retinopathy but it can not treat damages already caused by retinopathy. The researchers say more study has to be done to find out possible side effects with the combination treatment before starting human trials. Co-author of the study is Dr. Tuhina Prasad, a postdoctoral associate, College of Medicine, University of Florida and the study findings were published in the Investigative Ophthalmology and Visual Science journal.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below):

Also related to this story
1. Risks To Depression And Anxiety With Diabetic Retinopathy
2. Study On Diabetic retinopathy
3. Wearable Devices Market
4. Wearable Device To Alleviate Stress and Anxiety
5. About Esysta device

 



Categories

Sitemap 1   Sitemap 2   Sitemap 3   Sitemap 4

 

The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.